X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.
Lead Product(s): Enarodustat
Therapeutic Area: Hematology Product Name: Onnaro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2023
Details:
The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Salubris Biotherapeutics
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
Details:
Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Carlyle
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
